Rare Diseases and Otorhinolaryngology, Head and Neck Surgery

Abstract

Rare diseases pose multiple challenges for patients, relatives, physicians, nursing staff, and therapists. Their rarity impedes research and treatments due to medical and economical reasons. Many diseases in the field otorhinolaryngology, head and neck surgery are rare diseases due to their low prevalence. The initiation of the right management processes requires knowledge about diagnostics, resources like centers, networks and registries, about specifics of the physician-patient relationship, follow-up care including communication with family doctors and the role of self-help groups. Of special interest for university hospitals and our scientific society are the specific aspects of research including European networks and research funding, information management, public relations, education, training, financing, and regulations like orphan drugs and clinical trials in small populations.

Key words

rare diseases - otorhinolaryngology - medical ethics - orphan drugs

Publication History

Article published online:
30 April 2021

• Literatur

• 1 Krause F. Shared Decision Making bei seltenen Erkrankungen. Ethik Med 2019; 31: 131-141
• 2 Bundesgesundheitsministerium. Gesundheitsgefahren. Seltene Erkrankungen. In: https://www.bundesgesundheitsministerium.de/themen/praevention/gesundheitsgefahren/seltene-erkrankungen.html, abgerufen 25.10.2020
• 3 Enzyklopädie WDf. Seltene Krankheit. In: https://de.wikipedia.org/ wiki/Seltene_Krankheit#cite_ref-1, abgerufen 25. Oktober 2020
• 4 [Anonym]. Bundesinstitut für Arzneimittel und Medizinprodukte. Orphanet. Das Portal für seltene Krankheiten und Orphan Drugs. In: https://www.orpha.net/consor/cgi-bin/index.php abgerufen 25. Oktober 2020
• 5 [Anonym]. Bundesinstitut für Arzneimittel und Medizinprodukte. Orphanet Deutschland. In: https://www.bfarm.de/DE/Forschung/ Orphanet/_node.html, abgerufen 25. Oktober 2020;
• 6 [Anonym]. Orphan Drug Act of 1983; Pub L. No. 97, 414, 96 Stat. 2049. In
• 7 Le TT. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs. Adv Exp Med Biol 2017; 1031: 183-196
• 8 „vom“, DOI,
• 9 Vokinger KN, Kesselheim AS. Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU. BMJ Open 2019; 9: e028634
• 10 Herder M. What Is the Purpose of the Orphan Drug Act?. PLoS Med 2017; 14: e1002191
• 11 Kesselheim AS, Treasure CL, Joffe S. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. PLoS Med 2017; 14: e1002190
• 12 Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: a flood of orphan drugs and abuses?. Am J Law Med 2005; 31: 365-380
• 13 Rai AK. Pharmacogenetic interventions, orphan drugs, and distributive justice: the role of cost-benefit analysis. Soc Philos Policy 2002; 19: 246-270
• 14 Meekings KN, Williams CS, Arrowsmith JE. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012; 17: 660-664
• 15 Hasford J, Koch A. Ethical aspects of clinical trials in rare diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 556-562
• 16 McMenamin M, Berglind A, Wason JMS. Improving the analysis of composite endpoints in rare disease trials. Orphanet J Rare Dis 2018; 13: 81
• 17 Ristl R, Urach S, Rosenkranz G. et al. Methods for the analysis of multiple endpoints in small populations: A review. J Biopharm Stat 2019; 29: 1-29
• 18 Nateqi J, Lin S, Krobath H. et al. From symptom to diagnosis-symptom checkers re-evaluated : Are symptom checkers finally sufficient and accurate to use? An update from the ENT perspective. HNO 2019; 67: 334-342
• 19 Sonntag D. Artificial intelligence in medicine-the wrong track or promise of cure?. HNO 2019; 67: 343-349
• 20 Beaulieu-Jones BK, Finlayson SG, Yuan W. et al. Examining the Use of Real-World Evidence in the Regulatory Process. Clin Pharmacol Ther 2020; 107: 843-852
• 21 Franklin JM, Pawar A, Martin D. et al. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther 2020; 107: 817-826
• 22 O'Donnell JC, Le TK, Dobrin R. et al. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncol 2021; 17: 333-347
• 23 Wu J, Wang C, Toh S. et al. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions. Pharmacoepidemiol Drug Saf 2020; 29: 1213-1218
• 24 [Anonym]. EMA/CHMP guideline on clinical trials in small populations. In 2006
• 25 Day S, Jonker AH, Lau LPL. et al. Recommendations for the design of small population clinical trials. Orphanet J Rare Dis 2018; 13: 195
• 26 Jonker AHM, Lau A, Ando LPL, Baroldi Y, Bretz P, Burman F, Collignon CF, Hamdani O, Hemmings M, Hilgers RJ, Irony RD, Karlsson I, Kirschner M, Krischer J, Larsson JP, Leeson-Beevers K, Molenberghs K, O’Connor G, Posch D, Roes M, Schaefer KC, Scott F, Senn J, Stallard SJ, Thompson N, Torres A, Zohar F, Ayme S, Day S. , S. Small Population Clinical Trials: Challenges in the Field of Rare Diseases. In. 2016
• 27 Beauchamp TL, Childress JF. Principles of Biomedical Ethics. Oxford: Oxford University Press; 2001
• 28 Gericke CA, Riesberg A, Busse R. Ethical issues in funding orphan drug research and development. J Med Ethics 2005; 31: 164-168
• 29 Lowes LP, Alfano LN, Arnold WD. et al. Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatr Neurol 2019; 98: 39-45
• 30 Grill M, Kempmann A. Zolgensma: Wie das teuerste Medikament entstand. In 2020
• 31 WHO. World Health Organisation. World Development Report. 1993; Investing in Health. In; 1993
• 32 Pabst JY. Medicaments orphelins: quelques aspects juridiques, ethiques et economiques. Rev Epidemiol Sante Publique 2001; 49: 387-396
• 33 Kacetl J, Maresova P, Maskuriy R. et al. Ethical Questions Linked to Rare Diseases and Orphan Drugs - A Systematic Review. Risk Manag Healthc Policy 2020; 13: 2125-2148
• 34 He X, Urip BA, Zhang Z. et al. Evolving AAV-delivered therapeutics towards ultimate cures. J Mol Med (Berl). 2021 16. 1-25
• 35 Mendell JR, Al-Zaidy SA, Rodino-Klapac LR. et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther 2021; 29: 464-488
• 36 Oppel F, Schurmann M, Shao S. et al. Perspectives of genome editing in otorhinolaryngology. HNO 2019; 67: 184-189
• 37 Singer DRJR K. What is ahead for health policy and technology in the 2020s?. Health Policy Technol 2020; 9: 3-4
• 38 Makoski K. Erste Erfahrungen mit der ambulanten spezialfachärztlichen Versorgung nach § 116b SGB V. Gesundheit und Pflege. 2017 2. . 47–52
• 39 Freund A. Die zulassungsüberschreitende Anwendung von Humanarzneimitteln (Off-Label-Use) in Deutschland Pharmazeutische Unternehmer, Vertragsärzte, Patienten und Versicherte im Spannungsfeld von Arzneimittel-, und Sozialrecht sowie zivil- und strafrechtlicher Haftung. PharmR. 2004 8. . 275-299
• 40 Heinemann AK. Off-label Use von Diagnostika am Beispiel der MR-Kontrastmittel. Medizin Produkte Recht 2007; 10: 113-140
• 41 Willis R. The Works of William Harvey. London: Sydenham Society; 1847
• 42 Lochmuller H, Torrent IFJ, Le Cam Y. et al. The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact. Eur J Hum Genet 2017; 25: 1293-1302